Accumulating evidence showed that targeting autophagy alone or in combination with chemotherapy has been effective at enhancing cell death and improved the efficacy of the cancer therapies in a variety of cancer types.3 Our group has previously shown that inhibiting autophagy enhances cell-killing effects of Src inhibitors in CaP.5 We hypothesized that autophagy is a survival mechanism that prostate cancer cells used to evade the insult of androgen deprivation or antiandrogen therapy, including the new generation of ARSI, ENZA. Here, SRC is linked to cancer.